Scarica l'app Stockscreener
1.30
5.80%
-0.08
Dopo l'orario di chiusura:
1.31
0.01
+0.77%
Precedente Chiudi:
$1.38
Aprire:
$1.34
Volume 24 ore:
53,947
Relative Volume:
0.78
Capitalizzazione di mercato:
$28.99M
Reddito:
-
Utile/perdita netta:
$-61.06M
Rapporto P/E:
-0.0907
EPS:
-14.3261
Flusso di cassa netto:
$-59.30M
1 W Prestazione:
-13.33%
1M Prestazione:
-24.86%
6M Prestazione:
-59.12%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.2701
$1.38
Intervallo di 1 settimana:
$1.2701
$1.58
Portata 52W:
$1.2701
$12.65
Boundless Bio Inc Stock (BOLD) Company Profile
Nome
Boundless Bio Inc
Settore
Industria
Telefono
(858) 766-9912
Indirizzo
10955 ALEXANDRIA WAY, SAN DIEGO
Confronta BOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.30 | 28.99M | 0 | -61.06M | -59.30M | -14.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-22 | Iniziato | Guggenheim | Buy |
| 2024-04-22 | Iniziato | Leerink Partners | Outperform |
| 2024-04-22 | Iniziato | Piper Sandler | Overweight |
Boundless Bio Inc Borsa (BOLD) Ultime notizie
Boundless Bio stock plunges to 52-week low of $1.41 - Investing.com
Boundless Bio to Participate in the Needham Virtual Healthcare Conference - TradingView
Boundless Bio plans $14.5M stock sale via Jefferies By Investing.com - Investing.com Australia
Boundless Bio plans $14.5M stock sale via Jefferies - Investing.com India
Boundless Bio Inc Files For Mixed Shelf Of Up To $400 MillionSEC Filing - MarketScreener
Boundless Bio’s 2024 Financial Results and Strategic Progress - MSN
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Boundless Bio Inc. (BOLD) reports earnings - Quartz
Boundless Bio Reports Fourth Quarter And Full Year 2024 Financial Results And Business Highlights - Marketscreener.com
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - The Manila Times
Boundless Bio's $152M War Chest Fuels Breakthrough Cancer Drug Development - Stock Titan
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation - Yahoo Finance
What Will Boundless Bio Reveal at the Leerink Conference? CEO Set for Key Presentation - StockTitan
J&J vet jumps to Affinia—Chutes & Ladders - Fierce Biotech
Francisco Ballester to retire from Sandoz - biocentury.com
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer -February 03, 2025 at 10:00 am EST - Marketscreener.com
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Oncology Drug Development Expert Behind TRK Inhibitors Joins Boundless Bio as CMO - StockTitan
Beta Bionics targets IPO of up to $120M - BioWorld Online
Apellis COO stepping down to take first CEO job—Chutes & Ladders - Fierce Biotech
Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer - BioSpace
Neomorph Appoints Dr. Klaus Wagner as Chief Medical Officer - citybiz
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy - MSN
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development - Business Wire
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Layoffs Continued Across Biopharma in 2024 - BioSpace
The Escalator: Boundless Bio, Intelliguard, Klick Health and more - MM+M Online
Guggenheim Downgrades Boundless Bio (BOLD) - MSN
Boundless Bio Announces Pipeline and Leadership Updates - The Manila Times
Genesis hires Shifeng Pan as CSO, names Paul Friedman chair - BioCentury
Boundless Bio, Inc. Changes to Management Team - Marketscreener.com
Boundless Bio Won't Advance Cancer Treatment Trial, Executives to Step Down - MarketWatch
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Amgen names Howard Chang head of research and CSO - BioCentury
Amgen names Stanford geneticist and biotech founder to CSO post - Endpoints News
Science Spotlight: How extrachromosomal DNA drives cancer - BioCentury
Extrachromosomal DNA acts as joker for cancer cells - BioWorld Online
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Stanford Scientists Overturn Mendel’s Law With Shocking Cancer Discovery - SciTechDaily
Stanford researchers unveil the key role of extrachromosomal DNA in cancer - News-Medical.Net
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - The Manila Times
Boundless Bio Inc Azioni (BOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):